Results 21 to 30 of about 8,618 (210)

Silencing of microRNA-106b-5p prevents doxorubicin-mediated cardiotoxicity through modulation of the PR55α/YY1/sST2 signaling axis

Molecular Therapy: Nucleic Acids, 2023
Clinical use of doxorubicin (Dox), an anthracycline with potent anti-tumor effects, is limited because of its highly chemotherapy-induced cardiotoxicity (CIC).
A. Lax, F. Soler, M. J. Fernández Del Palacio, Silvia Pascual-Oliver, Miriam Ruiz Ballester, J. Fuster, D. Pascual-Figal, M. Asensio-Lopez   +7 more
semanticscholar   +1 more source

Circulating Soluble Suppression of Tumorigenicity 2 Predicts Recurrence After Radiofrequency Ablation of Persistent Atrial Fibrillation

Frontiers in Cardiovascular Medicine, 2021
Objective: A more extensively fibrotic left atrium contributes to atrial fibrillation (AF) occurrence, persistence, and recurrence. The soluble suppression of tumorigenicity 2 (sST2) has emerged as a ventricular fibrotic biomarker for patients with heart
Ruopeng Tan, Ruopeng Tan, Haixu Yu, Xu Han, Yang Liu, Xiaolei Yang, Yun-Long Xia, Yun-Long Xia, Xiaomeng Yin   +8 more
doaj   +1 more source

Paltusotine, a novel oral once-daily nonpeptide SST2 receptor agonist, suppresses GH and IGF-1 in healthy volunteers

Pituitary, 2022
Evaluate the pharmacodynamics, pharmacokinetics, and safety of paltusotine, an orally bioavailable, nonpeptide, somatostatin receptor subtype 2 (SST2) agonist being developed for the treatment of acromegaly and neuroendocrine tumors. A randomized, double-
A. Madan, S. Markison, S. Betz, A. Krasner, Rosa Luo, Theresa Jochelson, J. Lickliter, R. Struthers   +7 more
semanticscholar   +1 more source

Discovery of Paltusotine (CRN00808), a Potent, Selective, and Orally Bioavailable Non-peptide SST2 Agonist

ACS Medicinal Chemistry Letters, 2022
The discovery of a novel 4-(4-aminopiperidinyl)-3,6-diarylquinoline series of potent SST2 agonists is described. This class of molecules exhibit excellent selectivity over SST1, SST3, SST4, and SST5 receptors. The compound 3-[4-(4-aminopiperidin-1-yl)-3-(
Jian Zhao, Shimiao Wang, S. Markison, S. H. Kim, Sangdon Han, Mi Chen, A. Kusnetzow, Elizabeth Rico-Bautista, M. Johns, Rosa Luo, R. Struthers, A. Madan, Yunfei Zhu, S. Betz   +13 more
semanticscholar   +1 more source

Diagnostic Value of sST2 in Cardiovascular Diseases: A Systematic Review and Meta-Analysis

Frontiers in Cardiovascular Medicine, 2021
Biomarkers such as B-type natriuretic peptide (BNP), N-terminal pro-BNP (NT-proBNP), cardiac troponin (cTn), and CK-MB contribute significantly to the diagnosis of cardiovascular disease (CVD).
Tianyi Zhang, Chengyang Xu, Rui Zhao, Z. Cao   +3 more
semanticscholar   +1 more source

Effects of liraglutide vs. lifestyle changes on soluble suppression of tumorigenesis-2 (sST2) and galectin-3 in obese subjects with prediabetes or type 2 diabetes after comparable weight loss

Cardiovascular Diabetology, 2022
Background Soluble suppression of tumorigenesis-2 (sST2) and galectin (Gal)-3 are two biomarkers related to inflammation, metabolic disturbances and to myocardial fibrosis that characterize several cardiac pathological conditions.
P. Simeone, Romina Tripaldi, A. Michelsen, T. Ueland, R. Liani, S. Ciotti, K. Birkeland, H. Gulseth, A. Di Castelnuovo, F. Cipollone, P. Aukrust, A. Consoli, B. Halvorsen, F. Santilli   +13 more
semanticscholar   +1 more source

Role of soluble ST2 in short-term prediction of acute heart failure in acute ST-elevation myocardial infarction

Российский кардиологический журнал, 2021
Aim. To investigate the relationship of soluble ST2 (sST2) to acute heart failure (AHF) and compare the predictive value of sST2 and brain natriuretic peptide in patients with ST-elevation myocardial infarction (STEMI).Material and methods.
O. S. Donirova, K. V. Protasov, B. A. Donirov, E. V. Batunova   +3 more
doaj   +1 more source

The pro-inflammatory marker soluble suppression of tumorigenicity-2 (ST2) is reduced especially in diabetic morbidly obese patients undergoing bariatric surgery

Cardiovascular Diabetology, 2020
Background High soluble suppression of tumorigenicity-2 (sST2) is a marker of poor prognosis in chronic inflammatory conditions. ST2 and its ligand interleukin (IL)-33 are elevated in adipose tissue of obese individuals.
Svitlana Demyanets, Christoph Kaun, Alexandra Kaider, Walter Speidl, Manfred Prager, Stanislav Oravec, Philipp Hohensinner, Johann Wojta, Gersina Rega-Kaun   +8 more
doaj   +1 more source

STADE‐HF (sST2 As a help for management of HF): a pilot study

ESC Heart Failure, 2020
Aims Biomarkers are not recommended until now to guide the management of patients with heart failure (HF). Soluble suppression of tumorigenicity 2 (sST2) appears as a promising biomarker. The current study considered pre‐discharged sST2 values as a guide
Fabien Huet, Jean Nicoleau, Anne‐Marie Dupuy, Corentin Curinier, Cyril Breuker, Audrey Castet‐Nicolas, Manuela Lotierzo, Eran Kalmanovich, Laetitia Zerkowski, Mariama Akodad, Jérôme Adda, Audrey Agullo, Florence Leclercq, Jean‐Luc Pasquie, Pascal Battistella, Camille Roubille, Pierre Fesler, Grégoire Mercier, Guillaume Bourel, Jean‐Paul Cristol, François Roubille   +20 more
doaj   +1 more source

The serum levels and clinical significance of interleukin-33 and soluble ST2 in patients with vitiligo

Pifu-xingbing zhenliaoxue zazhi, 2020
Objective: To investigate the clinical significance of interleukin-33(IL-33) and soluble ST2 (sST2) in patients with vitiligo. Methods: The serum concentrations of IL-33 and sST2 were determined by enzyme linked immunosorbent assay (ELISA) respectively ...
Li YANG, Dong-qing LU, Han MA
doaj   +1 more source